Non-Small Cell Lung Cancer Clinical Trials

A listing of 142 Non-Small Cell Lung Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Non-Small Cell Lung Cancer

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 142 active clinical trials seeking participants for Non-Small Cell Lung Cancer research studies. The states with the highest number of trials for Non-Small Cell Lung Cancer participants are California, Texas, Florida and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

Featured Trial

High Triglyceride Clinical Research Study

Recruiting

Living with high triglycerides? See if our clinical study is right for you.
Don’t let financial stress hold you back. All clinical study-related assessments, care, and the investigational study drug are available at no cost. You could also be eligible for compensation for travel.

Conditions:

High Triglycerides

High Triglyceride Level

Hypertriglyceridemia

Elevated Triglycerides

Triglycerides High

Learn More

A Pilot Study of Blood-based Biomarkers for Response to Immune Checkpoint Inhibitors

NCT06630429

Recruiting

We propose to conduct a pilot study evaluating baseline and on-treatment changes in tumor fraction (TFx) in peripheral blood in patients with NSCLC and RCC being treated with checkpoint inhibitor therapy as part of standard of care. The primary objective of the study is to determine whether baseline TFx can be reliably predicted in patients with NSCLC and RCC and if changes can be detected during treatment that may correlate with response. Exploratory analyses will be completed to assess the pot... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

10/04/2024

Locations: The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Conditions: Non-Small Cell Lung Cancer, Renal Cell Carcinoma (RCC)

Learn More ›

FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

NCT06303505

Recruiting

The purpose of this multicentric, open label trial (NAPISTAR 1-01) is to evaluate the safety/tolerability, pharmacokinetics and preliminary efficacy of TUB-040 and to find the best dose of TUB-040 in patients with ovarian cancer and Non Small Cell Lung Cancer. TUB-040 is an antibody-drug-conjugate which delivers a topoisomerase I inhibitor to tumor cells which overexpress the target NaPi2b. The study consists of two parts: In dose escalation, ovarian cancer patients and lung cancer patients rece... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/06/2024

Locations: Christ Hospital, Cincinnati, Ohio +9 locations

Conditions: Ovarian Cancer, Non-small Cell Lung Cancer

Learn More ›

A Phase 1 Study of LNCB74 in Advanced Solid Tumors

NCT06774963

Recruiting

This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: Dana-Farber Cancer Institute, Boston, Massachusetts +3 locations

Conditions: Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer, Non-Small Cell Lung Cancer, Advanced or Metastatic Solid Tumors

Learn More ›

AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol)

NCT06333951

Recruiting

The study aims to determine maximum tolerated dose (MTD) or recommended combination dose of the MTA-cooperative PRMT5 inhibitor AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced methylthioadenosine phosphorylase (MTAP)-deleted thoracic tumors. The study also aims to determine the safety profile of AMG 193 administered in combination with other therapies in adult participants with metastatic or locally advanced MTAP-deleted thoracic... Read More

Gender:

ALL

Ages:

Between 18 years and 100 years

Trial Updated:

02/19/2025

Locations: Comprehensive Blood and Cancer Center, Bakersfield, California +33 locations

Comprehensive Blood and Cancer Center, Bakersfield, California

City of Hope National Medical Center, Duarte, California

Translational Research in Oncology US Inc, Trio Central Pharmacy, Los Angeles, California

University of California Irvine, Orange, California

University of California Los Angeles, Santa Monica, California

Rocky Mountain Cancer Centers, Denver, Colorado

Eastern Connecticut Hematology and Oncology Associates, Norwich, Connecticut

HealthPartners Institute, Saint Paul, Minnesota

Saint Lukes Hospital of Kansas City, Kansas City, Missouri

Comprehensive Cancer Centers of Nevada, Las Vegas, Nevada

New York University Grossman School of Medicine, New York, New York

Perlmutter Cancer Center at New York University Langone Hospital----Long Island, New York, New York

Hightower Clinical, Oklahoma City, Oklahoma

University of Tennessee Medical Center Knoxville, Knoxville, Tennessee

Baylor Charles A Sammons Cancer Center, Dallas, Texas

Texas Oncology - Dallas Fort Worth, Dallas, Texas

US Oncology Research Investigational Products Center, Dallas, Texas

Oncology Consultants Cancer Center, Houston, Texas

Texas Oncology Northeast Texas, Tyler, Texas

Virginia Cancer Specialists PC, Fairfax, Virginia

Northwest Medical Specialties, PLLC, Tacoma, Washington

Orange Health Service, Orange, New South Wales

The Queen Elizabeth Hospital, Woodville South, South Australia

Guangdong Provincial Peoples Hospital, Guangzhou, Guangdong

Queen Mary Hospital, The University of Hong Kong, Hong Kong, Not set

Prince of Wales Hospital, Chinese University of Hong Kong, Shatin, New Territories, Not set

Centro Ricerche Cliniche Di Verona Societa responsabilita limitata, Verona, Not set

Aichi Cancer Center, Nagoya-shi, Aichi

National Cancer Center Hospital East, Kashiwa-shi, Chiba

Shizuoka Cancer Center, Sunto-gun, Shizuoka

Wakayama Medical University Hospital, Wakayama-shi, Wakayama

Asan Medical Center, Seoul, Not set

National Cheng Kung University Hospital, Tainan, Not set

Taipei Veterans General Hospital, Taipei, Not set

Conditions: Thoracic Tumors, Non-small Cell Lung Cancer

Learn More ›

A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

NCT05877599

Recruiting

Phase I Study of NT-175, an autologous T cell therapy product genetically engineered to express an HLA-A\*02:01-restricted T cell receptor (TCR), targeting TP53 R175H mutant solid tumors.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: City of Hope, Duarte, California +8 locations

Conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer

Learn More ›

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

NCT06561386

Recruiting

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Local Institution - 0368, Tucson, Arizona +257 locations

Local Institution - 0368, Tucson, Arizona

Local Institution - 0111, Los Angeles, California

Local Institution - 0112, Los Angeles, California

Local Institution - 0304, Sacramento, California

Local Institution - 0159, San Francisco, California

Local Institution - 0206, Miami, Florida

Local Institution - 0162, Pembroke Pines, Florida

Local Institution - 0358, Saint Petersburg, Florida

Florida Cancer Specialists - East, West Palm Beach, Florida

Saint Elizabeth Medical Center Edgewood, Edgewood, Kentucky

Hattiesburg Clinic Hematology/Oncology, Hattiesburg, Mississippi

Bozeman Health Deaconess Hospital, Bozeman, Montana

Renown Regional Medical Center, Reno, Nevada

Local Institution - 0346, Paterson, New Jersey

Local Institution - 0381, Albuquerque, New Mexico

Local Institution - 0357, Bronx, New York

Local Institution - 0356, Hawthorne, New York

Local Institution - 0392, New York, New York

Local Institution - 0380, Northport, New York

Local Institution - 0325, Rochester, New York

Local Institution - 0324, Syracuse, New York

Local Institution - 0369, Canton, Ohio

Local Institution - 0199, Cleveland, Ohio

Local Institution - 0366, Massillon, Ohio

Lancaster General Hospital - Ann B Barshinger Cancer Institute, Lancaster, Pennsylvania

Local Institution - 0359, Abilene, Texas

Local Institution - 0305, Harlingen, Texas

Local Institution - 0378, Houston, Texas

The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center, Tyler, Texas

Local Institution - 0302, Salt Lake City, Utah

Local Institution - 0379, Ciudad autónoma de Buenos Aires, Buenos Aires

Instituto Alexander Fleming, Ciudad Autónoma de Buenos Aires, Buenos Aires

Local Institution - 0236, Mar del Plata, Buenos Aires

Local Institution - 0219, ABB, Ciudad Autónoma De Buenos Aires

Instituto Médico Río Cuarto, Río Cuarto, Córdoba

Sanatorio Parque, Rosario, Santa Fe

Local Institution - 0370, Córdoba, Not set

Hospital Privado Universitario de Córdoba, Córdoba, Not set

Gosford Hospital, Gosford, New South Wales

Local Institution - 0061, St Leonards, New South Wales

Local Institution - 0243, Brisbane, Queensland

Gallipoli Medical Research Ltd, Brisbane, Queensland

Local Institution - 0057, Elizabeth Vale, South Australia

Box Hill Hospital, Box Hill, Victoria

Local Institution - 0053, Murdoch, Western Australia

St. John of God Murdoch Hospital, Murdoch, Western Australia

Local Institution - 0314, Krems, Niederösterreich

Local Institution - 0292, Wels, Oberösterreich

Local Institution - 0294, Feldkirch, Not set

Local Institution - 0293, Wien, Not set

Local Institution - 0396, Edegem, Antwerpen

Local Institution - 0039, Brussels, Bruxelles-Capitale, Région De

Local Institution - 0187, Hasselt, Limburg

Local Institution - 0038, Yvoir, Namur

Local Institution - 0041, Roeselare, West-Vlaanderen

Local Institution - 0382, Fortaleza, Ceará

Local Institution - 0078, Belo Horizonte, Minas Gerais

Local Institution - 0375, Belem, Pará

Local Institution - 0151, Natal, Rio Grande Do Norte

Local Institution - 0083, Porto Alegre, Rio Grande Do Sul

Local Institution - 0076, Porto Alegre, Rio Grande Do Sul

Local Institution - 0084, Itajaí, Santa Catarina

Local Institution - 0152, Barretos, São Paulo

Local Institution - 0149, Bauru, São Paulo

Local Institution - 0373, São Caetano do Sul, São Paulo

Local Institution - 0232, Rio de Janeiro, Not set

Local Institution - 0147, São Paulo, Not set

Orlandi Oncologia, Santiago, Región Metropolitana De Santiago

Fundacion Arturo Lopez Perez (FALP), Santiago, Región Metropolitana De Santiago

Pontificia Universidad Catolica de Chile, Santiago, Región Metropolitana De Santiago

Bradfordhill, Santiago, Región Metropolitana De Santiago

Local Institution - 0182, Hefei, Anhui

Local Institution - 0070, Beijing, Beijing

Local Institution - 0238, Chongqing, Chongqing

Local Institution - 0244, Wanzhou, Chongqing

Local Institution - 0075, Fuzhou, Fujian

Local Institution - 0098, Guangzhou, Guangdong

Local Institution - 0307, Guangzhou, Guangdong

Local Institution - 0067, Guangzhou, Guangdong

Local Institution - 0326, Huizhou, Guangdong

Local Institution - 0353, Liuzhou, Guangxi

Local Institution - 0134, Nanning, Guangxi

Local Institution - 0102, Harbin, Heilongjiang

Local Institution - 0420, Xinxiang, Henan

Local Institution - 0237, Zhengzhou, Henan

Local Institution - 0235, Wuhan, Hubei

Local Institution - 0072, Changsha, Hunan

Local Institution - 0354, Huai'an, Jiangsu

Local Institution - 0181, Shenyang, Liaoning

Local Institution - 0423, Xi'an, Shaanxi

Local Institution - 0074, Jinan, Shandong

Local Institution - 0064, Shanghai, Shanghai

Local Institution - 0280, Shanghai, Shanghai

Local Institution - 0318, Shanghai, Shanghai

Local Institution - 0435, Taiyuan, Shanxi

Local Institution - 0121, Chengdu, Sichuan

Local Institution - 0424, Neijiang, Sichuan

Local Institution - 0177, Tianjin, Tianjin

Local Institution - 0071, Hangzhou, Zhejiang

Local Institution - 0099, Hangzhou, Zhejiang

Local Institution - 0338, Hangzhou, Zhejiang

Local Institution - 0101, Linhai, Zhejiang

Local Institution - 0415, Medellín, Antioquia

Local Institution - 0417, Valledupar, Cesar

Local Institution - 0443, Bogotá, Distrito Capital De Bogotá

Local Institution - 0418, Bogotá, Distrito Capital De Bogotá

Local Institution - 0416, Pereira, Risaralda

Local Institution - 0442, Cali, Valle Del Cauca

Local Institution - 0198, Aarhus, Midtjylland

Local Institution - 0124, Soenderborg, Syddanmark

Local Institution - 0125, Copenhagen, Not set

Local Institution - 0092, Montpellier, Hérault

Local Institution - 0093, Rennes, Ille-et-Vilaine

Local Institution - 0395, Vandoeuvre lès Nancy, Meurthe-et-Moselle

Local Institution - 0096, Lille, Nord-Pas-de-Calais

Local Institution - 0091, Toulon, Provence-Alpes-Côte-d'Azur

Local Institution - 0157, Pierre-Bénite, Rhône

Local Institution - 0421, Bayonne, Not set

Local Institution - 0158, Marseille, Not set

Local Institution - 0089, Paris, Not set

Local Institution - 0095, Paris, Not set

Local Institution - 0284, Esslingen, Baden-Württemberg

Local Institution - 0439, Ulm, Baden-Württemberg

Local Institution - 0287, Kempten, Bayern

Local Institution - 0347, München, Bayern

Local Institution - 0281, Frankfurt, Hessen

Local Institution - 0313, Marburg, Hessen

Local Institution - 0436, Hannover, Niedersachsen

Local Institution - 0397, Herne, Nordrhein-Westfalen

Local Institution - 0438, Münster, Nordrhein-Westfalen

Local Institution - 0437, Chemnitz, Sachsen

Local Institution - 0316, Grosshansdorf, Schleswig-Holstein

Local Institution - 0283, Bad Berka, Thüringen

Local Institution - 0285, Berlin, Not set

Local Institution - 0282, Bonn, Not set

Local Institution - 0288, Essen, Not set

Local Institution - 0286, Gauting, Not set

Local Institution - 0317, Heidelberg, Not set

Local Institution - 0329, New Delhi, Delhi

Local Institution - 0337, New Delhi, Delhi

Local Institution - 0333, Bengaluru, Karnataka

Local Institution - 0331, Thiruvananthapuram, Kerala

Local Institution - 0336, Mumbai, Maharashtra

Local Institution - 0328, Howrah, West Bengal

Local Institution - 0367, Dublin, Not set

Local Institution - 0028, Dublin, Not set

Local Institution - 0029, Dublin, Not set

Local Institution - 0027, Dublin, Not set

Local Institution - 0045, Monza, Lombardia

Local Institution - 0046, Naples, Napoli

Local Institution - 0049, Naples, Napoli

Local Institution - 0043, Bari, Puglia

Local Institution - 0250, Rome, Roma

Local Institution - 0221, Peschiera del Garda, Verona

Local Institution - 0222, Ravenna, Not set

Local Institution - 0312, Kashiwa, Chiba

University of Occupational and Enviromental Health, Kitakyushu, Fukuoka

Kurume University Hospital, Kurume, Fukuoka

Chugoku Central Hospital, Fukuyama-shi, Hiroshima

National Hospital Organization Hokkaido Cancer Center, Sapporo, Hokkaido

Kanagawa cancer center, Yokohama, Kanagawa

Local Institution - 0339, Sendai, Miyagi

Nara Medical University Hospital, Kashihara, Nara

Local Institution - 0279, Niigata-shi, Niigata

Kurashiki Central Hospital, Kurashiki, Okayama

Kansai Medical University Hospital, Hirakata, Osaka

Local Institution - 0277, Osaka-sayama, Osaka

Saitama Medical University International Medical Center, Hidaka, Saitama

Hamamatsu University Hospital, Hamamatsu, Shizuoka

Local Institution - 0310, Nagaizumi-cho,Sunto-gun, Shizuoka

The Cancer Institute Hospital of JFCR, Koto, Tokyo

Hyogo Cancer Center, Akashi, Not set

Fukushima Medical University, Fukushima, Not set

Local Institution - 0340, Osaka, Not set

Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do [Chungbuk]

Gachon University Gil Medical Center, Namdong-gu, Incheon-gwangyeoksi [Incheon]

National Cancer Center, Goyang-si, Kyǒnggi-do

Severance Hospital, Yonsei University Health System, Seoul, Seoul-teukbyeolsi [Seoul]

Asan Medical Center, Seoul, Seoul-teukbyeolsi [Seoul]

Samsung Medical Center, Seoul, Seoul-teukbyeolsi [Seoul]

Local Institution - 0170, Guadalajara, Jalisco

Local Institution - 0168, Santiago de Queretaro, Querétaro

Local Institution - 0172, Mexico, Not set

Local Institution - 0169, San Luis Potosí, Not set

Local Institution - 0030, Harderwijk, Gelderland

Local Institution - 0193, Heerlen, Limburg

Local Institution - 0196, Den Bosch, Noord-Brabant

Local Institution - 0195, Zwolle, Overijssel

Local Institution - 0036, Leiden, Zuid-Holland

Local Institution - 0315, The Hague, Zuid-Holland

Local Institution - 0033, Arnhem, Not set

Local Institution - 0032, Groningen, Not set

Local Institution - 0407, Tauranga, Bay Of Plenty

Local Institution - 0447, Tauranga, Bay Of Plenty

Local Institution - 0405, Auckland, Not set

Local Institution - 0425, Dunedin, Not set

Local Institution - 0406, Wellington, Not set

Local Institution - 0259, Warsaw, Mazowieckie

Local Institution - 0258, Prabuty, Pomorskie

Local Institution - 0255, Konin, Wielkopolskie

Local Institution - 0261, Poznan, Wielkopolskie

Local Institution - 0256, Skorzewo, Wielkopolskie

Local Institution - 0257, Koszalin, Zachodniopomorskie

Local Institution - 0260, Bydgoszcz, Not set

Local Institution - 0254, Łódź, Łódzkie

Local Institution - 0402, Lisbon, Lisboa

Local Institution - 0404, Coimbra, Not set

Local Institution - 0403, Porto, Not set

Local Institution - 0401, Porto, Not set

Local Institution - 0296, Bucharest, București

Local Institution - 0298, Bucharest, București

Local Institution - 0299, Florești, Cluj

Local Institution - 0295, Craiova, Dolj

Local Institution - 0297, Ploiești, Prahova

Local Institution - 0301, Cluj, Not set

Local Institution - 0300, Iași, Not set

Local Institution - 0408, Riyadh, Ar Riyāḑ

Local Institution - 0440, Dammam, Ash Sharqīyah

Local Institution - 0409, Jeddah, Makkah Al Mukarramah

Local Institution - 0429, Johannesburg, Gauteng

Local Institution - 0432, Pretoria, Gauteng

Local Institution - 0427, Sandton, Gauteng

Local Institution - 0431, Soweto, Gauteng

Local Institution - 0428, Cape Town, Western Cape

Local Institution - 0270, A Coruña, A Coruña [La Coruña]

Local Institution - 0264, Barcelona, Barcelona [Barcelona]

Local Institution - 0434, Barcelona, Catalunya [Cataluña]

Local Institution - 0267, L'Hospitalet de Llobregat, Catalunya [Cataluña]

Local Institution - 0414, Palma, Illes Balears [Islas Baleares]

Local Institution - 0413, Madrid, Madrid, Comunidad De

Local Institution - 0265, Madrid, Madrid, Comunidad De

Local Institution - 0411, Valencia, València

Local Institution - 0266, Málaga, Not set

Local Institution - 0268, Sevilla, Not set

Local Institution - 0269, València, Not set

Local Institution - 0289, st.Gallen, Sankt Gallen

Local Institution - 0341, Bellinzona, Ticino

Local Institution - 0291, Lausanne, Vaud

Local Institution - 0290, Basel, Not set

Local Institution - 0398, Münsterlingen, Not set

Taipei Medical University Shuang Ho Hospital, New Taipei, Not set

Taichung Veterans General Hospital, Taichung, Not set

Local Institution - 0116, Taipei, Not set

Taipei Veterans General Hospital, Taipei, Not set

Local Institution - 0361, Adana, Not set

Local Institution - 0365, Adana, Not set

Local Institution - 0383, Ankara, Not set

Local Institution - 0362, Ankara, Not set

Local Institution - 0410, Istanbul, Not set

Local Institution - 0364, Istanbul, Not set

Local Institution - 0441, Exeter, Devon

Local Institution - 0271, Larbert, Falkirk

Local Institution - 0189, Glasgow, Glasgow City

Local Institution - 0021, London, Kensington And Chelsea

Local Institution - 0348, London, London, City Of

Local Institution - 0001, London, London, City Of

Local Institution - 0020, Manchester, Not set

Local Institution - 0024, Wirral, Not set

Conditions: Non-small Cell Lung Cancer

Learn More ›

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895

Recruiting

This is a Phase III, randomised, double-blind, placebo-controlled, multicentre, international study assessing the efficacy and safety of durvalumab (MEDI4736) and domvanalimab (AB154) compared with durvalumab plus placebo in adults with locally advanced (Stage III), unresectable NSCLC whose disease has not progressed following definitive platinum-based cCRT.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Research Site, Chandler, Arizona +246 locations

Research Site, Chandler, Arizona

Research Site, Phoenix, Arizona

Research Site, Fountain Valley, California

Research Site, Santa Rosa, California

Research Site, Washington, District of Columbia

Research Site, Jacksonville, Florida

Research Site, Orlando, Florida

Research Site, Saint Augustine, Florida

Research Site, Macon, Georgia

Research Site, Elmhurst, Illinois

Research Site, Maywood, Illinois

Research Site, Naperville, Illinois

Research Site, Louisville, Kentucky

Research Site, Baltimore, Maryland

Research Site, Silver Spring, Maryland

Research Site, Detroit, Michigan

Research Site, Minneapolis, Minnesota

Research Site, Rochester, Minnesota

Research Site, East Brunswick, New Jersey

Research Site, Florham Park, New Jersey

Research Site, Buffalo, New York

Research Site, Johnson City, New York

Research Site, Asheville, North Carolina

Research Site, Charlotte, North Carolina

Research Site, Winston-Salem, North Carolina

Research Site, Columbus, Ohio

Research Site, Oklahoma City, Oklahoma

Research Site, Pittsburgh, Pennsylvania

Research Site, Charleston, South Carolina

Research Site, Nashville, Tennessee

Research Site, Fort Sam Houston, Texas

Research Site, Arlington, Virginia

Research Site, Fort Belvoir, Virginia

Research Site, Spokane Valley, Washington

Research Site, Appleton, Wisconsin

Research Site, Brussels, Not set

Research Site, Edegem, Not set

Research Site, Haine-Saint-Paul, Not set

Research Site, Leuven, Not set

Research Site, Liege, Not set

Research Site, Sint-Niklaas, Not set

Research Site, Barretos, Not set

Research Site, Londrina, Not set

Research Site, Porto Alegre, Not set

Research Site, Porto Velho, Not set

Research Site, Rio de Janeiro, Not set

Research Site, Santo Andre, Not set

Research Site, Sao Paulo, Not set

Research Site, São Paulo, Not set

Research Site, Taubaté, Not set

Research Site, Calgary, Alberta

Research Site, Kelowna, British Columbia

Research Site, Laval, Quebec

Research Site, Montreal, Quebec

Research Site, Las Condes, Not set

Research Site, Puerto Montt, Not set

Research Site, Santiago, Not set

Research Site, Temuco, Not set

Research Site, Aix en Provence, Not set

Research Site, Angers, Not set

Research Site, Bobigny, Not set

Research Site, Clermont-Ferrand, Not set

Research Site, Lille, Not set

Research Site, Paris Cedex 14, Not set

Research Site, Pau cedex, Not set

Research Site, Quimper, Not set

Research Site, Saint Gregoire, Not set

Research Site, Saint-Quentin cedex, Not set

Research Site, Vantoux, Not set

Research Site, Villeurbanne, Not set

Research Site, Berlin-Zehlendorf, Not set

Research Site, Berlin, Not set

Research Site, Braunschweig, Not set

Research Site, Chemnitz, Not set

Research Site, Erlangen, Not set

Research Site, Essen, Not set

Research Site, Georgsmarienhuette, Not set

Research Site, Giessen, Not set

Research Site, Halle, Not set

Research Site, Hamburg, Not set

Research Site, Homburg, Not set

Research Site, Koblenz, Not set

Research Site, Krefeld, Not set

Research Site, Köln, Not set

Research Site, Löwenstein, Not set

Research Site, Moers, Not set

Research Site, München, Not set

Research Site, Regensburg, Not set

Research Site, Tübingen, Not set

Research Site, Athens, Not set

Research Site, Holargos, Athens, Not set

Research Site, Thessaloniki, Not set

Research Site, Hong Kong, Not set

Research Site, Budapest, Not set

Research Site, Deszk, Not set

Research Site, Győr, Not set

Research Site, Salgótarján, Not set

Research Site, Székesfehérvár, Not set

Research Site, Törökbálint, Not set

Research Site, Ahmedabad, Not set

Research Site, Bangalore, Not set

Research Site, Delhi, Not set

Research Site, Gurgaon, Not set

Research Site, Howrah, Not set

Research Site, Hyderabad, Not set

Research Site, Jaipur, Not set

Research Site, Kolkata, Not set

Research Site, Marg Jaipur, Not set

Research Site, Mohali, Not set

Research Site, Namakkal, Not set

Research Site, New Delhi, Not set

Research Site, Varanasi, Not set

Research Site, Bergamo, Not set

Research Site, Roma, Not set

Research Site, Rozzano, Not set

Research Site, Udine, Not set

Research Site, Bunkyo-ku, Not set

Research Site, Chiba-shi, Not set

Research Site, Fukuoka-shi, Not set

Research Site, Hidaka-shi, Not set

Research Site, Hirosaki-shi, Not set

Research Site, Itabashi-ku, Not set

Research Site, Kashihara-shi, Not set

Research Site, Koto-ku, Not set

Research Site, Kumamoto-shi, Not set

Research Site, Matsuyama-shi, Not set

Research Site, Nagoya-shi, Not set

Research Site, Osaka-shi, Not set

Research Site, Osakasayama-shi, Not set

Research Site, Sapporo-shi, Not set

Research Site, Sunto-gun, Not set

Research Site, Tokyo, Not set

Research Site, Yokohama-shi, Not set

Research Site, Daegu, Not set

Research Site, Goyang-si, Not set

Research Site, Incheon, Not set

Research Site, Jinju-si, Not set

Research Site, Seoul, Not set

Research Site, Johor Bahru, Not set

Research Site, Kuala Lumpur, Not set

Research Site, Kuching, Not set

Research Site, Selangor, Not set

Research Site, Aguascalientes, Not set

Research Site, Cdmx, Not set

Research Site, Chihuahua, Not set

Research Site, Guadalajara, Not set

Research Site, Monterrey, Not set

Research Site, Oaxaca, Not set

Research Site, San Pedro Garza Garcia, Not set

Research Site, Sonora, Not set

Research Site, Veracruz, Not set

Research Site, Bodø, Not set

Research Site, Gjøvik, Not set

Research Site, Oslo, Not set

Research Site, Trondheim, Not set

Research Site, Bacolod, Not set

Research Site, Iloilo City, Not set

Research Site, Muntinlupa City, Not set

Research Site, Pasig City, Not set

Research Site, Quezon City, Not set

Research Site, Białystok, Not set

Research Site, Gliwice, Not set

Research Site, Katowice, Not set

Research Site, Wroclaw, Not set

Research Site, Zielona Góra, Not set

Research Site, Łódź, Not set

Research Site, Bucuresti, Not set

Research Site, Craiova, Not set

Research Site, Floresti, Not set

Research Site, Iasi, Not set

Research Site, Oradea, Not set

Research Site, Sibiu, Not set

Research Site, Suceava, Not set

Research Site, Timisoara, Not set

Research Site, Amanzimtoti, Not set

Research Site, Cape Town, Not set

Research Site, Johannesburg, Not set

Research Site, Parktown, Not set

Research Site, Pretoria, Not set

Research Site, Bilbao (Vizcaya), Not set

Research Site, Castello de la Plana, Not set

Research Site, Cordoba, Not set

Research Site, El Palmar, Not set

Research Site, Palma de Mallorca, Not set

Research Site, Sabadell (Barcelona), Not set

Research Site, Basel, Not set

Research Site, Bern, Not set

Research Site, Lausanne, Not set

Research Site, Hsinchu, Not set

Research Site, New-Taipei, Not set

Research Site, Taichung, Not set

Research Site, Tainan, Not set

Research Site, Taipei, Not set

Research Site, Taoyuan, Not set

Research Site, Bangkok, Not set

Research Site, Hat Yai, Not set

Research Site, Adapazari, Not set

Research Site, Ankara, Not set

Research Site, Antalya, Not set

Research Site, Edirne, Not set

Research Site, Istanbul, Not set

Research Site, Izmir, Not set

Research Site, Konya, Not set

Research Site, Çankaya, Not set

Research Site, Birmingham, Not set

Research Site, Brighton, Not set

Research Site, Cambridge, Not set

Research Site, Cardiff, Not set

Research Site, Cheltenham, Not set

Research Site, High Heaton/Newcastle Upon Tyn, Not set

Research Site, Leeds, Not set

Research Site, London, Not set

Research Site, Nottingham, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

A Study Investigating BG-60366 in Adults With Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

NCT06685718

Recruiting

This is an open-label, multicenter, Phase 1a/1b clinical study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of BG-60366, a highly potent, selective EGFR-mutation targeted Chimeric Degradation Activation Compound (CDAC). BG-60366 is designed to degrade mutant EGFR, which is a common cause for Non-Small Cell Lung Cancer (NSCLC). This study will evaluate how well BG-60366 works in participants with advanced or metastatic EGFR-mutant NS... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: University of Colorado, Denver, Colorado +38 locations

University of Colorado, Denver, Colorado

University of Miami, Miami, Florida

Dana Farber Cancer Institute, Boston, Massachusetts

Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri

Memorial Sloan Kettering Cancer Center Mskcc, New York, New York

Ohio State University, Columbus, Ohio

The University of Texas Md Anderson Cancer Center, Houston, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Liverpool Hospital, Liverpool, New South Wales

Princess Alexandra Hospital, Brisbane, Queensland

Cancer Research South Australia, Adelaide, South Australia

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Liga Norte Riograndene Contra O Cancer, Natal, Not set

Hospital Sao Lucas Da Pucrs, Porto Alegre, Not set

Hospital Sao Rafael (Rede Dor), Salvador, Not set

Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto, Sao Jose do Rio Preto, Not set

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, Not set

Hospital Israelita Albert Einstein, Sao Paulo, Not set

Hospital Santa Rita de Cassia Afecc, Vitoria, Not set

Beijing Cancer Hospital, Beijing, Beijing

Guangdong Provincial Peoples Hospital Huifu Branch, Guangzhou, Guangdong

The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch, Nanning, Guangxi

The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi

Shanxi Bethune Hospital, Taiyuan, Shanxi

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang

Irccs Azienda Ospedaliero Universitaria Bologna, Bologna, Not set

Fondazione Irccs San Gerardo Dei Tintori Sc Oncologia, Monza, Not set

Fondazione Policlinico Universitario Agostino Gemelli, Roma, Not set

Sarawak General Hospital, Kuching, Not set

Harbour Cancer and Wellness, Auckland, Not set

Hospital Universitario Vall Dhebron, Barcelona, Not set

Hospital Universitario de Octubre, Madrid, Not set

H Puerta de Hierro Majadahonda, Madrid, Not set

Ramathibodi Hospital Mahidol University, Bangkok, Not set

Songklanagarind Hospital (Prince of Songkhla University), Hat Yai, Not set

Srinagarind Hospital (Khon Kaen University), Muang, Not set

Conditions: Non-Small Cell Lung Cancer, Lung Cancer, NSCLC, NSCLC (Non-small Cell Lung Carcinoma), EGFR Activating Mutation, EGFR Mutation-Related Tumors

Learn More ›

A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

NCT06695845

Recruiting

The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Arizona Oncology Associates, PC - NAHOA, Prescott, Arizona +13 locations

Conditions: Breast Cancer, Gastric Cancer, Esophageal Cancer, Gastroesophageal Cancer, Colorectal Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Ovarian Cancer, Urothelial Carcinoma, Salivary Gland Cancer, Pancreatic Cancer, HER-2 Protein Overexpression

Learn More ›

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

NCT05899608

Recruiting

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Summit Therapeutics Research Center, Tucson, Arizona +59 locations

Summit Therapeutics Research Center, Tucson, Arizona

Summit Therapeutics Research Center, Little Rock, Arkansas

Summit Therapeutics Research Center, Los Angeles, California

Summit Therapeutics Research Center, Sacramento, California

Summit Therapeutics Research Center, Santa Monica, California

Summit Therapeutics Research Center, Santa Rosa, California

Summit Therapeutics Research Center, Lone Tree, Colorado

Summit Therapeutics Research Center, Fort Myers, Florida

Summit Therapeutics Research Center, Jacksonville, Florida

Summit Therapeutics Research Center, Ocala, Florida

Summit Therapeutics Research Center, Palm Bay, Florida

Summit Therapeutics Research Center, Pensacola, Florida

Summit Therapeutics Research Center, Petersburg, Florida

Summit Therapeutics Research Center, Plantation, Florida

Summit Therapeutics Research Center, Saint Petersburg, Florida

Summit Therapeutics Research Center, Tallahassee, Florida

Summit Therapeutics Research Center, West Palm Beach, Florida

Summit Therapeutics Research Center, Lexington, Kentucky

Summit Therapeutics Research Center, Burlington, Massachusetts

Summit Therapeutics Research Center, Ann Arbor, Michigan

Summit Therapeutics Research Center, Detroit, Michigan

Summit Therapeutics Research Center, Saint Paul, Minnesota

Summit Therapeutics Research Center, Billings, Montana

Summit Therapeutics Research Center, New York, New York

Summit Therapeutics Research Center, Chapel Hill, North Carolina

Summit Therapeutics Research Center, Charlotte, North Carolina

Summit Therapeutics Research Center, Cincinnati, Ohio

Summit Therapeutics Research Center, Cleveland, Ohio

Summit Therapeutics Research Center, Eugene, Oregon

Summit Therapeutics Research Center, Nashville, Tennessee

Summit Therapeutics Research Center, Austin, Texas

Summit Therapeutics Research Center, Dallas, Texas

MD Anderson Cancer Center, Houston, Texas

Summit Therapeutics Research Center, Tyler, Texas

Summit Therapeutics Research Center, Norfolk, Virginia

Summit Therapeutics Research Center, Reston, Virginia

Summit Therapeutics Research Center, Seattle, Washington

Summit Therapeutics Research Center, Spokane, Washington

Summit Therapeutics Research Center, Madison, Wisconsin

Summit Therapeutics Research Center, London, Ontario

Summit Therapeutics Research Center, Ottawa, Ontario

Summit Therapeutics Research Center, Regina, Saskatchewan

Summit Therapeutics Research Center, Esslingen, Not set

Summit Therapeutics Research Center, Frankfurt, Not set

Summit Therapeutics Research Center, Giesen, Not set

Summit Therapeutics Research Center, Heidelberg, Not set

Summit Therapeutics Research Center, Jena, Not set

Summit Therapeutics Research Center, Kempten, Not set

Summit Therapeutics Research Center, Dublin, Not set

Summit Therapeutics Research Center, Poznań, Not set

Summit Therapeutics Research Center, Łódź, Not set

Summit Therapeutics Research Center, Belgrade, Not set

Summit Therapeutics Research Center, Kragujevac, Not set

Summit Therapeutics Research Center, Niš, Not set

Summit Therapeutics Research Center, London, Not set

Summit Therapeutics Research Center, Manchester, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors

NCT06120283

Recruiting

This is a dose escalation and dose expansion study to compare how well BGB-43395, a cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with either fulvestrant or letrozole in participants with hormone receptor positive (HR+) and human epidermal growth factor 2 negative (HER2-) breast cancer (BC) and other advanced solid tumors. The main purpose of this study is to explore the recommended dosing for BGB-43395.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado +64 locations

Sarah Cannon Research Institute (Scri) At Health One, Denver, Colorado

Florida Cancer Specialists and Research Institute, Lake Mary, Florida

Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Duke Cancer Center, Durham, North Carolina

James Cancer Hospital and Solove Research Institute, Columbus, Ohio

Scri Oncology Partners, Nashville, Tennessee

The University of Texas Md Anderson Cancer Center, Houston, Texas

Next Dallas, Irving, Texas

Next Oncology, San Antonio, Texas

Blacktown Cancer and Haematology Centre, Blacktown, New South Wales

Southern Highlands Private Hospital, Bowral, New South Wales

Concord Repatriation General Hospital, Concord, New South Wales

Macquarie University, North Ryde, New South Wales

Townsville University Hospital, Douglas, Queensland

Genesiscare St Andrews, Adelaide, South Australia

Austin Health, Heidelberg, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Fundacao Pio Xii Hospital de Amor de Barretos, Barretos, Not set

Hospital Sirio Libanes Brasilia, Brasilia, Not set

Centro de Pesquisas Oncologicas Cepon, Florianopolis, Not set

Liga Norte Riograndene Contra O Cancer, Natal, Not set

Fundacao Universidade de Caxias Do Sul Instituto de Pesquisas Em Saude, Petropolis, Not set

Hospital Sao Lucas Da Pucrs Uniao Brasileira de Educacao E Assistencia, Porto Algre, Not set

Instituto Nacional de Cancer, Rio de Janeiro, Not set

Instituto Dor de Pesquisa E Ensino Hospital Sao Rafael, Salvador, Not set

Icesp Instituto Do Cancer Do Estado de Sao Paulo Octavio Frias de Oliveira, Sao Paulo, Not set

Clinica de Pesquisa E Centro de Estudos Em Oncologia Ginecologica E Mamaria, Sao Paulo, Not set

Hospital Israelita Albert Einstein, Sao Paulo, Not set

Beijing Cancer Hospital, Beijing, Beijing

Fujian Cancer Hospital, Fuzhou, Fujian

Sun Yat Sen Memorial Hospital, Sun Yat Sen University (South), Guangzhou, Guangdong

Harbin Medical University Cancer Hospital, Harbin, Heilongjiang

The First Affiliated Hospital of Nanchang University Branch Donghu, Nanchang, Jiangxi

Liaoning Cancer Hospital and Institute, Shenyang, Liaoning

Fudan University Shanghai Cancer Centerpudong, Shanghai, Shanghai

Centre de Lutte Contre Le Cancer Institut Bergonie, Bordeaux, Not set

Centre Francois Baclesse, Caen Cedex, Not set

Centre Oscar Lambret, Lille, Not set

Institut Paoli Calmettes, Marseille, Not set

Institut Curie, Paris, Not set

Centre Eugene Marquis, Rennes, Not set

Institut de Cancerologie de Louest, St Herblain, Not set

Institut Gustave Roussy, Villejuif, Not set

Nagoya University Hospital, Nagoya, Aichi

National Cancer Center Hospital East, Kashiwa, Chiba

Shizuoka Cancer Center, Suntogun, Shizuoka

Seoul National University Bundang Hospital, Seongnamsi, Gyeonggi-do

Korea University Anam Hospital, Seoul, Gyeonggi-do

Gachon University Gil Medical Center, Incheon, Incheon Gwang'yeogsi

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Severance Hospital Yonsei University Health System, Seoul, Seoul Teugbyeolsi

Asan Medical Center, Seoul, Seoul Teugbyeolsi

Samsung Medical Center, Seoul, Seoul Teugbyeolsi

The Catholic University of Korea, Seoul St Marys Hospital, Seoul, Seoul Teugbyeolsi

Pulau Pinang Hospital, Georgetown, Not set

University Malaya Medical Centre, Kuala Lumpur, Not set

Sarawak General Hospital, Kuching, Not set

National Cancer Institute (Institut Kanser Negara), Putrajaya, Not set

The Institute of Oncology, Arensia Exploratory Medicine, Chisinau, Not set

Harbour Cancer and Wellness, Auckland, Not set

Nzcr Christchurch, Christchurch, Not set

Siriraj Hospital, Bangkok, Not set

Banphaeo General Hospital, Banphaeo, Not set

Srinagarind Hospital (Khon Kaen University), Muang, Not set

Conditions: Advanced Solid Tumor, Advanced Breast Cancer, Metastatic Breast Cancer, Hormone-receptor-positive Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Hormone Receptor Positive Malignant Neoplasm of Breast, HER2-negative Breast Cancer, Hormone Receptor Positive HER-2 Negative Breast Cancer, Non-small Cell Lung Cancer

Learn More ›

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

NCT06236438

Recruiting

Non-Squamous Non-Small Cell Lung Cancer (NSCLC) remains a leading cause of cancer mortality worldwide, with poor survival prospects for metastatic disease. The purpose of this study is to evaluate the optimized dose, adverse events, and efficacy of livmoniplimab in combination with budigalimab plus chemotherapy versus pembrolizumab plus chemotherapy in participants with untreated metastatic non-squamous non-small cell lung cancer. Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination with budigalimab (another investigational drug) + chemotherapy, budigalimab +chemotherapy, or pembrolizumab +chemotherapy. In Stage 2, there are 2 treatments arms. Participants will either receive livmoniplimab (optimized dose) in combination with budigalimab +chemotherapy or placebo in combination with pembrolizumab +chemotherapy. Chemotherapy consists of IV Infused pemetrexed + IV infused cisplatin or IV infused or injected carboplatin. Approximately 840 adult participants will be enrolled in the study across 200 sites worldwide. Stage 1: In cohort 1, participants will receive intravenously (IV) infused livmoniplimab (dose A)+ IV infused budigalimab, + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + IV Infused pemetrexed. In cohort 2, participants will receive livmoniplimab (dose B) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In cohort 3, participants will receive budigalimab + chemotherapy for 4 cycles followed by budigalimab + pemetrexed . In cohort 4, participants will receive IV Infused pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. Stage 2: In arm 1, participants will receive livmoniplimab (dose optimized) + budigalimab + chemotherapy for 4 cycles followed by livmoniplimab + budigalimab + pemetrexed. In arm 2, participants will receive IV Infused placebo + pembrolizumab + chemotherapy for 4 cycles followed by pembrolizumab + pemetrexed. The estimated study duration is 55 months. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, questionnaires, and scans. Read Less

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/14/2025

Locations: Memorial Hospital West /ID# 262221, Pembroke Pines, Florida +30 locations

Memorial Hospital West /ID# 262221, Pembroke Pines, Florida

Bond Clinic /ID# 262611, Winter Haven, Florida

University Cancer & Blood Cent /ID# 261824, Athens, Georgia

University of Kansas Medical Center /ID# 263196, Westwood, Kansas

Baptist Health Lexington /ID# 261823, Lexington, Kentucky

Cancer & Hematology Centers of Western Michigan - East /ID# 261826, Grand Rapids, Michigan

Washington University-School of Medicine /ID# 262759, Saint Louis, Missouri

Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati, Ohio

Guthrie Robert Packer Hospital /ID# 262758, Sayre, Pennsylvania

Renovatio clinical /ID# 262000, El Paso, Texas

Houston Methodist Hospital /ID# 262722, Houston, Texas

Texas Oncology - Plano East /ID# 264356, Plano, Texas

Texas Oncology, P. A. /ID# 264311, San Antonio, Texas

Renovatio Clinical /ID# 261999, The Woodlands, Texas

Vista Oncology - East Olympia /ID# 262303, Olympia, Washington

The Canberra Hospital /ID# 261891, Garran, Australian Capital Territory

Nepean Hospital /ID# 262157, Kingswood, New South Wales

Westmead Hospital /ID# 261894, Westmead, New South Wales

Centro de Investigacion y Desarrollo Oncologico /ID# 261800, Temuco, Araucania

Oncored /Id# 261801, Vitacura, Region Metropolitana Santiago

Rambam Health Care Campus /ID# 262431, Haifa, H_efa

Shaare Zedek Medical Center /ID# 262432, Jerusalem, Yerushalayim

National Cancer Center Hospital East /ID# 261923, Kashiwa-shi, Chiba

Saitama Cancer Center /ID# 262703, Kitaadachi-gun, Saitama

National Cancer Center Hospital /ID# 261925, Chuo-ku, Tokyo

Pan American Center for Oncology Trials /ID# 269666, Rio Piedras, Not set

National Cheng Kung University Hospital /ID# 262016, Tainan, Not set

Mackay Memorial Hospital /ID# 262534, Taipei City, Not set

Taipei Medical University Hospital /ID# 262020, Taipei City, Not set

Linkou Chang Gung Memorial Hospital /ID# 262535, Taoyuan City, Not set

Gazi University Medical Faculty /ID# 261786, Ankara, Not set

Conditions: Non-Small Cell Lung Cancer

Learn More ›

Browse by State

Non-Small Cell Lung Cancer clinical trials in Alabama

Non-Small Cell Lung Cancer clinical trials in Alaska

Non-Small Cell Lung Cancer clinical trials in Arizona

Non-Small Cell Lung Cancer clinical trials in Arkansas

Non-Small Cell Lung Cancer clinical trials in California

Non-Small Cell Lung Cancer clinical trials in Colorado

Non-Small Cell Lung Cancer clinical trials in Connecticut

Non-Small Cell Lung Cancer clinical trials in Delaware

Non-Small Cell Lung Cancer clinical trials in District of Columbia

Non-Small Cell Lung Cancer clinical trials in Florida

Non-Small Cell Lung Cancer clinical trials in Georgia

Non-Small Cell Lung Cancer clinical trials in Hawaii

Non-Small Cell Lung Cancer clinical trials in Idaho

Non-Small Cell Lung Cancer clinical trials in Illinois

Non-Small Cell Lung Cancer clinical trials in Indiana

Non-Small Cell Lung Cancer clinical trials in Iowa

Non-Small Cell Lung Cancer clinical trials in Kansas

Non-Small Cell Lung Cancer clinical trials in Kentucky

Non-Small Cell Lung Cancer clinical trials in Louisiana

Non-Small Cell Lung Cancer clinical trials in Maine

Non-Small Cell Lung Cancer clinical trials in Montana

Non-Small Cell Lung Cancer clinical trials in Nebraska

Non-Small Cell Lung Cancer clinical trials in Nevada

Non-Small Cell Lung Cancer clinical trials in New Hampshire

Non-Small Cell Lung Cancer clinical trials in New Jersey

Non-Small Cell Lung Cancer clinical trials in New Mexico

Non-Small Cell Lung Cancer clinical trials in New York

Non-Small Cell Lung Cancer clinical trials in North Carolina

Non-Small Cell Lung Cancer clinical trials in North Dakota

Non-Small Cell Lung Cancer clinical trials in Ohio

Non-Small Cell Lung Cancer clinical trials in Oklahoma

Non-Small Cell Lung Cancer clinical trials in Oregon

Non-Small Cell Lung Cancer clinical trials in Maryland

Non-Small Cell Lung Cancer clinical trials in Massachusetts

Non-Small Cell Lung Cancer clinical trials in Michigan

Non-Small Cell Lung Cancer clinical trials in Minnesota

Non-Small Cell Lung Cancer clinical trials in Mississippi

Non-Small Cell Lung Cancer clinical trials in Missouri

Non-Small Cell Lung Cancer clinical trials in Pennsylvania

Non-Small Cell Lung Cancer clinical trials in Rhode Island

Non-Small Cell Lung Cancer clinical trials in South Carolina

Non-Small Cell Lung Cancer clinical trials in South Dakota

Non-Small Cell Lung Cancer clinical trials in Tennessee

Non-Small Cell Lung Cancer clinical trials in Texas

Non-Small Cell Lung Cancer clinical trials in Utah

Non-Small Cell Lung Cancer clinical trials in Vermont

Non-Small Cell Lung Cancer clinical trials in Virginia

Non-Small Cell Lung Cancer clinical trials in Washington

Non-Small Cell Lung Cancer clinical trials in West Virginia

Non-Small Cell Lung Cancer clinical trials in Wisconsin

Non-Small Cell Lung Cancer clinical trials in Wyoming